Rare Disease Day: How the patient voice can tear down barriers

To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unmet need is not only considerable, but varies considerably from condition to condition, individual to individual.